Efficacy of Tolebrutinib in Animal Studies on Multiple Sclerosis
The systematic review found that tolebrutinib significantly reduced the risk of confirmed disability progression in patients with secondary progressive multiple sclerosis (SPMS) and relapsing MS. Specifically, 18.35% risk reduction was observed at ≥3 months and 14.08% at ≥6 months. However, adverse events were common, occurring in about 76% of patients, though most were not serious.
- Tags
- #Other
- Most relevant to
- —
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
These findings are important as they suggest that tolebrutinib could be beneficial in managing disability progression in MS patients, highlighting its potential effectiveness.
What this does not prove
The findings are preliminary and not definitive; further research is required to confirm longevity and safety of tolebrutinib compared to existing therapies, and longer-term studies are essential.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- 4 · basis not reported
- Randomised
- Yes
- Controlled
- Yes
- Primary endpoint met
- Yes
- Relevant MS type
- SPMS, RRMS
- Publication date
- 2026-10-19
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Other
Original sources
- Primary evidenceEfficacy and safety of tolebrutinib in multiple sclerosis: a systematic review and meta-analysis. ↗DOI: 10.1007/s10072-026-09459-6
Supporting passages (12)
study designThis systematic review and meta-analysis bring together the available evidence on its clinical efficacy and adverse events.
subjectsFour publications met our inclusion criteria: three reporting four randomized controlled trials and one long-term extension study.
sample sizeFour publications met our inclusion criteria: three reporting four randomized controlled trials and one long-term extension study.
randomizedRESULTS: Four publications met our inclusion criteria: three reporting four randomized controlled trials and one long-term extension study.
controlledRESULTS: Four publications met our inclusion criteria: three reporting four randomized controlled trials and one long-term extension study.
primary endpoint metTolebrutinib reduced the risk of confirmed disability progression at both ≥3 and ≥6 months, and disability improvement at 6 months was numerically higher than with comparators, though not conclusively so.
research categoriesThis systematic review and meta-analysis bring together the available evidence on its clinical efficacy and adverse events.
relevant ms typesThe available trial evidence suggests that tolebrutinib may reduce confirmed disability progression in nonrelapsing secondary progressive MS and MRI inflammatory activity versus placebo in earlier-phase relapsing MS.
publication datePublication date: 2026-10-19
interventionTolebrutinib is an oral, brain-penetrant Bruton's tyrosine kinase (BTK) inhibitor being investigated for multiple sclerosis (MS).
findingsTolebrutinib reduced the risk of confirmed disability progression at both ≥3 and ≥6 months, and disability improvement at 6 months was numerically higher than with comparators, though not conclusively so.
limitationsTitle: Efficacy and safety of tolebrutinib in multiple sclerosis: a systematic review and meta-analysis.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.